M.J. Millward

1.0k total citations
31 papers, 842 citations indexed

About

M.J. Millward is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, M.J. Millward has authored 31 papers receiving a total of 842 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in M.J. Millward's work include Cancer Treatment and Pharmacology (8 papers), Cancer therapeutics and mechanisms (5 papers) and Lung Cancer Treatments and Mutations (5 papers). M.J. Millward is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Cancer therapeutics and mechanisms (5 papers) and Lung Cancer Treatments and Mutations (5 papers). M.J. Millward collaborates with scholars based in Australia, United Kingdom and United States. M.J. Millward's co-authors include Richard Kefford, G. S. Falchook, Georgina V. Long, Peter F. Lebowitz, J. R. Infante, Michael P. Brown, Hendrik‐Tobias Arkenau, Stephen Clarke, L. Goedhals and Michael Boyer and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

M.J. Millward

31 papers receiving 821 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.J. Millward Australia 13 580 403 340 71 55 31 842
A. D. Colevas United States 10 391 0.7× 355 0.9× 113 0.3× 14 0.2× 40 0.7× 24 652
Damiano Italy 6 634 1.1× 346 0.9× 446 1.3× 10 0.1× 47 0.9× 11 885
Martina Uttenreuther‐Fischer Germany 16 890 1.5× 350 0.9× 666 2.0× 23 0.3× 33 0.6× 32 1.1k
Erin Larkins United States 14 637 1.1× 286 0.7× 441 1.3× 17 0.2× 80 1.5× 28 937
Shakun Malik United States 18 454 0.8× 316 0.8× 455 1.3× 17 0.2× 97 1.8× 35 993
José Rodrigues Pereira Brazil 9 541 0.9× 419 1.0× 622 1.8× 19 0.3× 85 1.5× 16 915
Erina Hatashita Japan 15 579 1.0× 588 1.5× 492 1.4× 14 0.2× 126 2.3× 17 1.0k
Toshio Fujino Japan 16 420 0.7× 402 1.0× 563 1.7× 15 0.2× 105 1.9× 54 975
E. Levchenko Russia 12 510 0.9× 341 0.8× 451 1.3× 17 0.2× 61 1.1× 75 908
Brian Belmontes United States 13 421 0.7× 322 0.8× 203 0.6× 20 0.3× 40 0.7× 22 757

Countries citing papers authored by M.J. Millward

Since Specialization
Citations

This map shows the geographic impact of M.J. Millward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.J. Millward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.J. Millward more than expected).

Fields of papers citing papers by M.J. Millward

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.J. Millward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.J. Millward. The network helps show where M.J. Millward may publish in the future.

Co-authorship network of co-authors of M.J. Millward

This figure shows the co-authorship network connecting the top 25 collaborators of M.J. Millward. A scholar is included among the top collaborators of M.J. Millward based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.J. Millward. M.J. Millward is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harrison, Simon J., Laurence Catley, Timothy Price, et al.. (2015). Phase 1 clinical trial of marizomib (MRZ, NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 (NCT00629473) final results. Clinical Lymphoma Myeloma & Leukemia. 15. e269–e269. 2 indexed citations
2.
Gan, Hui, Noelia Nebot, J.C. Soria, et al.. (2012). 613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors. European Journal of Cancer. 48. 189–189. 3 indexed citations
3.
Mainwaring, Paul N., Jason D. Lickliter, Michael P. Brown, et al.. (2010). A multicenter, open-label phase Ib/II study to assess the safety and clinical activity of intravenous combretastatin A1 diphosphate (OXi4503) as monotherapy in subjects with primary or secondary hepatic tumor burden.. Journal of Clinical Oncology. 28(15_suppl). TPS164–TPS164. 1 indexed citations
4.
Nowak, Anna K., Roslyn J. Francis, Michael Byrne, et al.. (2006). 79 Use of 18F-FDG PET imaging in staging and prediction of survival for malignant pleural mesothelioma (MPM). Lung Cancer. 54. S19–S19. 3 indexed citations
5.
Kirkwood, John M., Agop Y. Bedikian, M.J. Millward, et al.. (2005). Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM). Journal of Clinical Oncology. 23(16_suppl). 7506–7506. 24 indexed citations
6.
Byrne, Michael, Roslyn J. Francis, A. van der Schaaf, et al.. (2005). O-074 Comparison of FDG-PET and CT scans to assess response to chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 49. S27–S28. 6 indexed citations
7.
Millward, M.J., Agop Y. Bedikian, Robert M. Conry, et al.. (2004). Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival. Journal of Clinical Oncology. 22(14_suppl). 7505–7505. 11 indexed citations
8.
Putti, Thomas C., Ka‐Fai To, Anthony T.�C. Chan, et al.. (2002). Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia–Pacific region. Histopathology. 41(2). 144–151. 59 indexed citations
9.
Clarke, Stephen, et al.. (2002). Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Annals of Oncology. 13(5). 737–741. 99 indexed citations
10.
11.
Kris, Mark G. & M.J. Millward. (1999). Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.. PubMed. 26(3 Suppl 10). 1–2. 14 indexed citations
12.
Toner, Guy C., Jeremy Shapiro, Christine Laidlaw, et al.. (1998). Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison.. Journal of Clinical Oncology. 16(12). 3874–3879. 20 indexed citations
13.
Zalcberg, John, M.J. Millward, J. Bishop, et al.. (1998). Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 16(5). 1948–1953. 81 indexed citations
14.
Ball, David, John W. Smith, James F. Bishop, et al.. (1997). A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer. British Journal of Cancer. 75(5). 690–697. 46 indexed citations
15.
Ghazal‐Aswad, Saad, M.J. Millward, N P Bailey, et al.. (1996). Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer.. Journal of Clinical Oncology. 14(3). 800–805. 11 indexed citations
16.
Millward, M.J., et al.. (1993). Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. British Journal of Cancer. 67(5). 1031–1035. 69 indexed citations
17.
Richardson, PG, et al.. (1992). Metastatic Melanoma to the Testis Simulating Primary Seminoma. British Journal of Urology. 69(6). 663–665. 7 indexed citations
18.
Millward, M.J., Alex Hendrick, & B.M.J. Cantwell. (1990). Fixed dose short course mitomyucin C with vincristine in advanced pre-treated breast cancer. Annals of Oncology. 1(5). 373–374. 3 indexed citations
19.
Millward, M.J., Shlomo Cohney, Michael Byrne, & Gail Ryan. (1990). Pulmonary toxicity following MOPP chemotherapy. Australian and New Zealand Journal of Medicine. 20(3). 245–248. 5 indexed citations
20.
Millward, M.J., Vinod Ganju, & Martin Buck. (1988). CARDIAC ARREST – A MANIFESTATION OF 5‐FLUOROURACIL CARDIOTOXICITY. Australian and New Zealand Journal of Medicine. 18(5). 693–695. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. D. Colevas Breakdown of academic impact, for papers by Damiano Breakdown of academic impact, for papers by Martina Uttenreuther‐Fischer Breakdown of academic impact, for papers by Erin Larkins Breakdown of academic impact, for papers by Shakun Malik Breakdown of academic impact, for papers by José Rodrigues Pereira Breakdown of academic impact, for papers by Erina Hatashita Breakdown of academic impact, for papers by Toshio Fujino Breakdown of academic impact, for papers by E. Levchenko Breakdown of academic impact, for papers by Brian Belmontes
Rankless by CCL
2026